For the main component of the growth strategy, the oncological tumor vaccine VCC-001 in the treatment of renal cell carcinoma, the EU patent that was promised in 2021 was granted in February 2022. Immediately afterwards, the national phases that followed the granting of the Connect Patents, initiated in the countries of Belgium, France, Spain, Austria, Switzerland, Germany, Great Britain, Italy, Ireland.
